Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc.verified

PIRS

Price:

$16.4849

Market Cap:

$21.76M

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; ...[Read more]

Industry

Biotechnology

IPO Date

2015-01-02

Stock Exchange

NASDAQ

Ticker

PIRS

The Enterprise Value as of September 2024 (TTM) for Pieris Pharmaceuticals, Inc. (PIRS) is 2.03M

According to Pieris Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.03M. This represents a change of 360.87% compared to the average of 441.13K of the last 4 quarters.

Pieris Pharmaceuticals, Inc. (PIRS) Historical Enterprise Value (quarterly & annually)

How has PIRS Enterprise Value performed in the past?

The mean historical Enterprise Value of Pieris Pharmaceuticals, Inc. over the last ten years is 93.73M. The current 2.03M Enterprise Value has changed 116.90% with respect to the historical average. Over the past ten years (40 quarters), PIRS's Enterprise Value was at its highest in in the June 2022 quarter at 11.05B. The Enterprise Value was at its lowest in in the June 2023 quarter at -17605738.88.

Quarterly (TTM)
Annual

Average

93.73M

Median

74.53M

Minimum

-1004352.00

Maximum

293.80M

Pieris Pharmaceuticals, Inc. (PIRS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Pieris Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 904.05%

Maximum Annual Enterprise Value = 293.80M

Minimum Annual Increase = -101.95%

Minimum Annual Enterprise Value = -1004352.00

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023-1004352.00-101.95%
202251.61M-63.15%
2021140.06M69.31%
202082.73M-39.71%
2019137.22M106.88%
201866.33M-77.42%
2017293.80M904.05%
201629.26M-40.78%
201549.41M-43.78%
201487.89M-17.21%

Pieris Pharmaceuticals, Inc. (PIRS) Average Enterprise Value

How has PIRS Enterprise Value performed in the past?

The current Enterprise Value of Pieris Pharmaceuticals, Inc. (PIRS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

63.56M

5-year avg

82.12M

10-year avg

93.73M

Pieris Pharmaceuticals, Inc. (PIRS) Enterprise Value vs. Peers

How is PIRS’s Enterprise Value compared to its peers?

Pieris Pharmaceuticals, Inc.’s Enterprise Value is less than Adaptimmune Therapeutics plc (119.37M), less than Mereo BioPharma Group plc (595.29M), less than PDS Biotechnology Corporation (78.58M), less than Leap Therapeutics, Inc. (37.18M), less than X4 Pharmaceuticals, Inc. (51.07M), less than Corvus Pharmaceuticals, Inc. (366.46M), less than Terns Pharmaceuticals, Inc. (574.47M), less than TCR2 Therapeutics Inc. (49.64M), less than Affimed N.V. (57.84M), less than ADC Therapeutics SA (124.37M), less than Agenus Inc. (450.10M), less than Inozyme Pharma, Inc. (408.51M), greater than Achilles Therapeutics plc (-61656377.00), less than Checkpoint Therapeutics, Inc. (100.08M), less than Cue Biopharma, Inc. (8.98M), greater than Medicenna Therapeutics Corp. (-25687000.00),

Build a custom stock screener for Pieris Pharmaceuticals, Inc. (PIRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pieris Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Pieris Pharmaceuticals, Inc. (PIRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Pieris Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Pieris Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Pieris Pharmaceuticals, Inc. (PIRS)?

What is the 3-year average Enterprise Value for Pieris Pharmaceuticals, Inc. (PIRS)?

What is the 5-year average Enterprise Value for Pieris Pharmaceuticals, Inc. (PIRS)?

How does the current Enterprise Value for Pieris Pharmaceuticals, Inc. (PIRS) compare to its historical average?